The present invention relates to an agent for reducing the side effects of kinase inhibitors, the agent containing at least one branched-chain amino acid selected from among isoleucine, leucine and valine or a salt thereof as an active ingredient, and also relates to an anticancer medicine containing at least one branched-chain amino acid selected from among isoleucine, leucine and valine or a salt thereof, and a kinase inhibitor.